305 related articles for article (PubMed ID: 26614233)
1. Rectal dose constraints for salvage iodine-125 prostate brachytherapy.
Peters M; Hoekstra CJ; van der Voort van Zyp JR; Westendorp H; van de Pol SM; Moerland MA; Maenhout M; Kattevilder R; van Vulpen M
Brachytherapy; 2016; 15(1):85-93. PubMed ID: 26614233
[TBL] [Abstract][Full Text] [Related]
2. Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints.
Peters M; van der Voort van Zyp J; Hoekstra C; Westendorp H; van de Pol S; Moerland M; Maenhout M; Kattevilder R; van Vulpen M
Radiother Oncol; 2015 Nov; 117(2):262-9. PubMed ID: 26349590
[TBL] [Abstract][Full Text] [Related]
3. Focal or whole-gland salvage prostate brachytherapy with iodine seeds with or without a rectal spacer for postradiotherapy local failure: How best to spare the rectum?
Guimas V; Quivrin M; Bertaut A; Martin E; Chambade D; Maingon P; Mazoyer F; Cormier L; Créhange G
Brachytherapy; 2016; 15(4):406-411. PubMed ID: 27317949
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer.
Hsu CC; Hsu H; Pickett B; Crehange G; Hsu IC; Dea R; Weinberg V; Gottschalk AR; Kurhanewicz J; Shinohara K; Roach M
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):370-7. PubMed ID: 22672747
[TBL] [Abstract][Full Text] [Related]
5. Placement of an absorbable rectal hydrogel spacer in patients undergoing low-dose-rate brachytherapy with palladium-103.
Taggar AS; Charas T; Cohen GN; Boonyawan K; Kollmeier M; McBride S; Mathur N; Damato AL; Zelefsky MJ
Brachytherapy; 2018; 17(2):251-258. PubMed ID: 29241706
[TBL] [Abstract][Full Text] [Related]
6. Salvage low-dose-rate permanent seed brachytherapy for locally recurrent prostate cancer: Association between dose and late toxicity.
Rose JN; Crook JM; Pickles T; Keyes M; Morris WJ
Brachytherapy; 2015; 14(3):342-9. PubMed ID: 25727178
[TBL] [Abstract][Full Text] [Related]
7. CT-based 3D dose-volume parameter of the rectum and late rectal complication in patients with cervical cancer treated with high-dose-rate intracavitary brachytherapy.
Kato S; Tran DN; Ohno T; Nakano T; Kiyohara H; Ohkubo Y; Kamada T
J Radiat Res; 2010; 51(2):215-21. PubMed ID: 20339256
[TBL] [Abstract][Full Text] [Related]
8. Predictors of toxicity after image-guided high-dose-rate interstitial brachytherapy for gynecologic cancer.
Lee LJ; Viswanathan AN
Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1192-7. PubMed ID: 22592049
[TBL] [Abstract][Full Text] [Related]
9. Late rectal toxicity after image-based high-dose-rate interstitial brachytherapy for postoperative recurrent and/or residual cervical cancers: EQD2 predictors for Grade ≥II toxicity.
Chopra S; Dora T; Engineer R; Mechanery S; Agarwal P; Kannan S; Ghadi Y; Swamidas J; Mahantshetty U; Shrivastava SK
Brachytherapy; 2015; 14(6):881-8. PubMed ID: 26409708
[TBL] [Abstract][Full Text] [Related]
10. Probability of late rectal morbidity in 125I prostate brachytherapy.
Waterman FM; Dicker AP
Int J Radiat Oncol Biol Phys; 2003 Feb; 55(2):342-53. PubMed ID: 12527047
[TBL] [Abstract][Full Text] [Related]
11. Dose to the bladder neck is the most important predictor for acute and late toxicity after low-dose-rate prostate brachytherapy: implications for establishing new dose constraints for treatment planning.
Hathout L; Folkert MR; Kollmeier MA; Yamada Y; Cohen GN; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):312-9. PubMed ID: 25304791
[TBL] [Abstract][Full Text] [Related]
12. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes.
Chen CP; Weinberg V; Shinohara K; Roach M; Nash M; Gottschalk A; Chang AJ; Hsu IC
Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):324-9. PubMed ID: 23474112
[TBL] [Abstract][Full Text] [Related]
13. Use of a rectal spacer with low-dose-rate brachytherapy for treatment of prostate cancer in previously irradiated patients: Initial experience and short-term results.
Mahal BA; Ziehr DR; Hyatt AS; Neubauer-Sugar EH; O'Farrell DA; O'Leary MP; Steele GS; Niedermayr TR; Beard CJ; Martin NE; Orio PF; D'Amico AV; Devlin PM; Nguyen PL
Brachytherapy; 2014; 13(5):442-9. PubMed ID: 24880584
[TBL] [Abstract][Full Text] [Related]
14. Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy.
Mbeutcha A; Chauveinc L; Bondiau PY; Chand ME; Durand M; Chevallier D; Amiel J; Kee DL; Hannoun-Lévi JM
Radiat Oncol; 2017 Mar; 12(1):49. PubMed ID: 28274241
[TBL] [Abstract][Full Text] [Related]
15. Impact of dosimetric and clinical parameters on clinical side effects in cervix cancer patients treated with 3D pulse-dose-rate intracavitary brachytherapy.
Levitchi M; Charra-Brunaud C; Quetin P; Haie-Meder C; Kerr C; Castelain B; Delannes M; Thomas L; Desandes E; Peiffert D
Radiother Oncol; 2012 Jun; 103(3):314-21. PubMed ID: 22633813
[TBL] [Abstract][Full Text] [Related]
16. The effect of obesity on rectal dosimetry after permanent prostate brachytherapy.
Patil N; Crook J; Saibishkumar EP; Aneja M; Borg J; Pond G; Ma C
Brachytherapy; 2009; 8(2):218-222. PubMed ID: 19230790
[TBL] [Abstract][Full Text] [Related]
17. Salvage brachytherapy in prostate local recurrence after radiation therapy: predicting factors for control and toxicity.
Henríquez I; Sancho G; Hervás A; Guix B; Pera J; Gutierrez C; Abuchaibe O; Martínez-Monge R; Tormo A; Polo A
Radiat Oncol; 2014 Apr; 9():102. PubMed ID: 24885287
[TBL] [Abstract][Full Text] [Related]
18. High-dose-rate brachytherapy boost for prostate cancer: Analysis of dose-volume histogram parameters for predicting late rectal toxicity.
Chicas-Sett R; Farga D; Perez-Calatayud MJ; Celada F; Roldan S; Fornes-Ferrer V; Ibanez-Rosello B; Tormo A; Benlloch JM; Perez-Calatayud J
Brachytherapy; 2017; 16(3):511-517. PubMed ID: 28366276
[TBL] [Abstract][Full Text] [Related]
19. A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526).
Crook JM; Zhang P; Pisansky TM; Trabulsi EJ; Amin MB; Bice W; Morton G; Pervez N; Vigneault E; Catton C; Michalski J; Roach M; Beyer D; Jani A; Horwitz E; Donavanik V; Sandler H
Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):335-343. PubMed ID: 30312717
[TBL] [Abstract][Full Text] [Related]
20. Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: A comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time.
Kollmeier MA; McBride S; Taggar A; Anderson E; Lin M; Pei X; Weiji S; Voros L; Cohen G; Yamada Y; Zelefsky MJ
Brachytherapy; 2017; 16(6):1091-1098. PubMed ID: 28838648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
